Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 51 - 100 out of 24,920

Document Document Title
WO/2019/078263A1
The present invention addresses the problem of providing a method for easily and efficiently preparing a functional and matured neuromuscular junction (NMJ) in vitro. This problem is solved by a method for producing an artificial neuromu...  
WO/2019/071353A1
A method of reducing glutamate efflux from skeletal muscle by inhibiting system Xc- activity is provided. The method is useful for the treatment of statin-induced myalgia. Pharmaceutical compositions useful to treat statin-induced myalgi...  
WO/2019/073507A1
Provided is a medicinal composition for preventing and/or treating amyotrophic lateral sclerosis (ALS), said composition containing a plexin A1 antagonist.  
WO/2019/068888A1
The present invention relates to the treatment of subjective tinnitus. More precisely, it concerns the administration of botulinum toxin into the scalp, neck and face muscles, especially in the temporalis muscle, of patients suffering fr...  
WO/2019/071147A1
The disclosure relates to methods and compositions including p38 kinase inhibitors and agents that regulate expression of DUX4 and downstream genes including but not restricted to ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDClL, RFPL2, CC...  
WO/2019/068604A1
The present invention relates to 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2 - b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one for use in the treatment of spinal muscular atrophy (SMA), its pharmaceutical composition to be...  
WO/2019/071144A1
The present invention relates to compositions and methods of inhibiting p38 kinase to reduce gene and protein expression of DUX4 and downstream genes regulated by DUX4. The present invention further relates to methods for treating patien...  
WO/2019/067979A1
The present disclosure relates to methods of treating Duchenne's Muscular Dystrophy by administering an antisense oligonucleotide that induces exon skipping and a non-steroidal anti- inflammatory compound.  
WO/2019/065928A1
The present invention addresses the problem of providing a compound for prophylaxis and/or treatment of inflammatory diseases of the central nervous system, or a pharmacologically acceptable salt thereof. Provided is a compound represent...  
WO/2019/067981A1
The present disclosure relates to methods of treating Duchenne's Muscular Dystrophy by administering an antisense oligonucleotide that induces exon skipping and a non-steroidal antiinflammatory compound.  
WO/2019/065791A1
Provided is a compound which has an MAGL inhibitory effect and is expected to be useful as a prophylactic or therapeutic agent for neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Hutchinson's disease, amyotrop...  
WO/2019/067975A1
The present disclosure relates to methods of treating Duchenne's Muscular Dystrophy by administering an antisense oligonucleotide that induces exon skipping and a non-steroidal anti- inflammatory compound.  
WO/2019/062662A1
Disclosed are a substituted pyrimidine piperazine compound of Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and a pharmaceuti...  
WO/2019/060297A1
Described herein are methods for mitochondrial transplantation wherein old, damaged, or mutated mitochondria are replaced with young, undamaged, or non-mutated mitochondria. The old, damaged, or mutated mitochondria can also be replaced ...  
WO/2019/059973A1
Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.  
WO/2019/058132A1
This invention relates to compounds that are inhibitors of the CDK12 kinase. The compounds are useful in the treatment of disorders mediated by CDK12 kinase including myotonic dystrophy type 1 (DM1) and other disorders caused by the gene...  
WO/2019/055832A1
Provided herein are compounds of Formula (I) and (II) and their salts, and compositions comprising such compounds that are useful for useful for modulating neutral sphingomyelinase 2 (n-SMase2) in cells. Also disclosed herein are methods...  
WO/2019/054106A1
A suppressor of extracellular matrix production by epidermal growth factor receptor (EGFR)-expressing cells, said suppressor comprising an EGFR inhibitor as an active ingredient.  
WO/2019/054430A1
The purpose of the present invention is to provide a compound having an anti-inflammatory action, a pharmacologically acceptable salt thereof, etc. A solving means of the present invention is a compound of general formula (1) or a pharma...  
WO/2019/055687A1
In one aspect, the disclosure relates to methods and compositions for treatment of cancer cachexia. In a further aspect, the composition is a pharmaceutical composition comprising a class l/IIB HDAC inhibitor and an androgen. In a still ...  
WO/2019/055536A1
The present invention features compositions and methods that enhance cell extravasation and/or muscle cell fusion, and methods for identifying genes that enhance or inhibit extravasation and muscle cell fusion. One aspect of the present ...  
WO/2019/054427A1
The present invention addresses the problem of providing a compound having an anti-inflammatory effect, a pharmacologically acceptable salt thereof, etc. The means for solution according to the present invention is a compound represented...  
WO/2019/050923A1
The disclosure is directed to methods of treating subjects exposed to nerve agents with dantrolene, or a pharmaceutically acceptable salt thereof.  
WO/2019/046903A1
The present disclosure provides a method of increasing muscle mass in a subject, the method comprising administering to the subject follistatin or a functional fragment thereof for a period of time and in an amount sufficient to effect a...  
WO/2019/046251A1
The disclosure is directed to pharmaceutical compositions comprising of Tizanidine or a pharmaceutically acceptable salt thereof which controllably modulate the onset of at least one secondary effect associated with Tizanidine administra...  
WO/2019/044788A1
The purpose of the present invention is to provide a topical dermatological composition capable of easily improving the body's ability to balance for ordinary non-athletes who do not actively perform everyday exercise, such as housewives...  
WO/2019/044894A1
The present invention addresses the problem of providing a compound having strong conjugating activity with respect to a modified collagen, a use of the compound as a modified collagen test drug and research reagent, and a composition co...  
WO/2019/041361A1
A compound of Formula (I), pharmaceutically acceptable salts thereof, and individual enantiomers or diastereomers thereof are disclosed. Compositions and methods useful for treatment or suppression of diseases, developmental delays and s...  
WO/2019/044964A1
The present invention provides an exercise efficiency-improving composition, a fatigue-reducing composition, and a dynamic visual acuity-improving composition characterized by containing a kaempferol analog.  
WO/2019/035405A1
Provided is a nonaqueous carbon dioxide external preparation in single dosage form, the external preparation comprising a paste base, carbonate, an acid and/or a substance which produces an acid by hydrolysis, and alcohol. Merely by bein...  
WO/2019/036471A1
Disclosed are compositions comprising branched chain amino acids, urea cycle amino acids and essential amino acids for use in treating or preventing liver diseases and disorders with hyperammonemia or muscle wasting in a subject.  
WO/2019/034059A1
The present invention relates to a compound and the application thereof in treating inflammation or inflammation-related diseases, and more specifically to a compound UTLOH combination. Said compound effectively inhibits the level of LPS...  
WO/2019/036267A1
Disclosed herein are methods for increasing circulating mesenchymal stem cells by administering a compound having the general formula 1 as defined herein, or a pharmaceutically acceptable salt thereof.  
WO/2019/031425A1
The present invention mainly addresses the problem of providing a novel therapeutic agent for a motor neuron disease. Provided are: a therapeutic agent for a motor neuron disease which is characterized by comprising, as an active ingredi...  
WO/2019/031442A1
Provided is a blood flow improver which is safe and has a mild action. This blood flow improver comprises S-1-propenylcysteine or a salt thereof as an active ingredient.  
WO/2019/031495A1
The present invention addresses the problem of providing a drug which is highly stable and which contains a pyrazolone derivative such as edaravone, but does not contain sodium bisulfite. The present invention provides a drug which is de...  
WO/2019/026930A1
The present invention provides a food composition for increasing muscle mass, muscle mass increasing agent, therapeutic agent for locomotive syndrome, therapeutic agent for sarcopenia, exercise function maintenance agent, muscle atrophy-...  
WO/2019/026302A1
An agonist of 67 kDa laminin receptor, said agonist comprising as an active ingredient oolong tea polymerized polyphenols or a derivative thereof.  
WO/2019/025474A1
The present invention relates to modulators of at least one endocannabinoid system component for use in i) the prevention and/or treatment of muscular dystrophy (MD) cardiomyopathy or other cardiomyopathies, and to pharmaceutical composi...  
WO/2019/021059A1
The present disclosure provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, and its therapeutic uses for activating a growth factor pathway, promoting wound healing, promoting tissue repair, and treating hea...  
WO/2019/022216A1
The purpose of the present invention is to provide an amino acid composition having the novel, heretofore uninvestigated use of improving muscle strength with reference to a healthy state in which exhaustion does not occur. The present i...  
WO/2019/021024A1
A method of treating lower limb spasticity in a subject, particularly one which is 18 years of age or under, comprising administering to the subject an effective amount of botulinum neurotoxin. A composition for use in treating lower lim...  
WO/2019/021135A1
Composition for promoting mitochondrial biogenesis and improving mitochondrial function in a subject, the composition comprising an active agent, said active agent containing the amino acids leucine, isoleucine, valine, threonine, lysine...  
WO/2019/022219A1
The purpose of the present invention is to provide a novel amino acid composition which can promote secretion of adrenaline and/or noradrenalin. The present invention relates to a noradrenaline secretion promoting amino acid composition ...  
WO/2019/014772A1
The present invention relates to a therapeutic antisense oligonucleotide which binds to exon 51 of the human dystrophin pre-mRNA to induce exon skipping, and conjugates and compositions thereof for the treatment of DMD.  
WO/2019/014774A1
In one aspect, a method of preconditioning stem cells comprising exposing stem cells to low dose radiation (LDR) is provided. In another aspect, a population of preconditioned stem cells is provided, wherein the population of 5 precondit...  
WO/2019/016505A1
The present invention relates to the use of 2-chloro-2'-deoxyadenosine, hereinafter referred to as cladribine, or a pharmaceutically acceptable salt thereof, for treating or ameliorating an autoimmune, neuromuscular disorder, e.g. the au...  
WO/2019/017338A1
Provided is a novel peptide. This peptide contains the amino acid sequence represented by SEQ ID NO: 18 and binds to an active protease, but does not bind to a precursor protease.  
WO/2019/014300A1
The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitor...  
WO/2019/014303A1
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This inve...  

Matches 51 - 100 out of 24,920